{"id":67791,"date":"2026-06-09T23:10:43","date_gmt":"2026-06-09T15:10:43","guid":{"rendered":"https:\/\/flcube.com\/?p=67791"},"modified":"2026-06-09T23:10:45","modified_gmt":"2026-06-09T15:10:45","slug":"remegen-secures-dual-nmpa-approvals-for-taiai-telitacicept-in-sjogrens-syndrome-and-iga-nephropathy-expanding-first-in-class-blys-april-inhibitor-franchise","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67791","title":{"rendered":"RemeGen Secures Dual NMPA Approvals for Tai&#8217;ai (Telitacicept) in Sj\u00f6gren&#8217;s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\/APRIL Inhibitor Franchise"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>RemeGen Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9995:HKG\">HKG: 9995<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688331:SHA\">SHA: 688331<\/a>) announced today that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted two additional indication approvals for <strong>Tai&#8217;ai<\/strong> (telitacicept): the <strong>injection formulation<\/strong> for <strong>Sj\u00f6gren&#8217;s syndrome<\/strong> (sicca syndrome) and the <strong>pre-filled syringe injection<\/strong> for <strong>IgA nephropathy<\/strong>, expanding the therapeutic reach of the world&#8217;s first dual-targeting BLyS\/APRIL inhibitor.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>Tai&#8217;ai (telitacicept)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>RemeGen Co., Ltd. (HKG: 9995, SHA: 688331)<\/td><\/tr><tr><td><strong>Approval Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>New Indications<\/strong><\/td><td>Sj\u00f6gren&#8217;s syndrome (injection) and IgA nephropathy (pre-filled syringe)<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td>World&#8217;s first approved recombinant fusion protein targeting both BLyS and APRIL<\/td><\/tr><tr><td><strong>Development Origin<\/strong><\/td><td>Independently developed by RemeGen<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-mechanism-of-action-dual-pathway-inhibition\" class=\"wp-block-heading\">Mechanism of Action \u2013 Dual Pathway Inhibition<\/h2>\n\n\n\n<h3 id=\"h-iga-nephropathy-application\" class=\"wp-block-heading\">IgA Nephropathy Application<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pathogenic Process<\/strong>: Excessive B cell activation leads to production of galactose-deficient IgA1 (Gd-IgA1) and immune complex deposition in glomeruli<\/li>\n\n\n\n<li><strong>Therapeutic Action<\/strong>: Simultaneous inhibition of BLyS and APRIL binding to B cell receptors blocks abnormal B cell differentiation and maturation<\/li>\n\n\n\n<li><strong>Clinical Outcome<\/strong>: Reduced Gd-IgA1 production and alleviated kidney damage<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-sjogren-s-syndrome-application\" class=\"wp-block-heading\">Sj\u00f6gren&#8217;s Syndrome Application<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Biology<\/strong>: Significantly elevated serum levels of BLyS and APRIL drive B cell abnormalities and immune system dysregulation<\/li>\n\n\n\n<li><strong>Therapeutic Action<\/strong>: Dual inhibition of BLyS and APRIL binding prevents pathological B cell activation<\/li>\n\n\n\n<li><strong>Clinical Outcome<\/strong>: Restoration of immune homeostasis and symptom improvement<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-product-portfolio-expansion\" class=\"wp-block-heading\">Product Portfolio Expansion<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Formulation<\/th><th>Indication<\/th><th>Key Features<\/th><\/tr><\/thead><tbody><tr><td><strong>Injection<\/strong><\/td><td>Sj\u00f6gren&#8217;s syndrome<\/td><td>Standard injectable formulation for autoimmune indication<\/td><\/tr><tr><td><strong>Pre-filled Syringe<\/strong><\/td><td>IgA nephropathy<\/td><td>Patient-friendly delivery system for chronic kidney disease management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Franchise Expansion<\/strong>: Builds on existing Tai&#8217;ai commercial foundation with two high-unmet-need indications<\/li>\n\n\n\n<li><strong>Dual-Target Differentiation<\/strong>: Unique mechanism addressing limitations of single-pathway inhibitors<\/li>\n\n\n\n<li><strong>Autoimmune Leadership<\/strong>: Strengthens RemeGen&#8217;s position in B-cell mediated autoimmune disorders<\/li>\n\n\n\n<li><strong>Commercial Synergy<\/strong>: Leverages existing manufacturing, distribution, and medical affairs infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sj\u00f6gren&#8217;s Syndrome<\/strong>: Affects approximately 0.5-1% of the global population with limited treatment options<\/li>\n\n\n\n<li><strong>IgA Nephropathy<\/strong>: Most common primary glomerulonephritis globally, with significant progression risk to end-stage renal disease<\/li>\n\n\n\n<li><strong>BLyS\/APRIL Market<\/strong>: Emerging therapeutic class with potential advantages over single-target approaches<\/li>\n\n\n\n<li><strong>China Autoimmune Market<\/strong>: Rapidly growing segment with increasing diagnosis rates and treatment accessibility<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding regulatory approvals, clinical development, market opportunities, and commercial expectations. Actual results may differ due to risks including market adoption, competitive dynamics, reimbursement challenges, and post-marketing safety surveillance requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060801487_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060801487_c.\"><\/object><a id=\"wp-block-file--media-8ae0262d-12f4-4240-aa3d-e1e97674e707\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060801487_c.pdf\">2026060801487_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060801487_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8ae0262d-12f4-4240-aa3d-e1e97674e707\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China&#8217;s National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,1155,15,375,1294],"class_list":["post-67791","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-hkg-9995","tag-product-approvals","tag-remegen","tag-sha-688331"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RemeGen Secures Dual NMPA Approvals for Tai&#039;ai (Telitacicept) in Sj\u00f6gren&#039;s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\/APRIL Inhibitor Franchise - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China&#039;s National Medical Products Administration (NMPA) has granted two additional indication approvals for Tai&#039;ai (telitacicept): the injection formulation for Sj\u00f6gren&#039;s syndrome (sicca syndrome) and the pre-filled syringe injection for IgA nephropathy, expanding the therapeutic reach of the world&#039;s first dual-targeting BLyS\/APRIL inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67791\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RemeGen Secures Dual NMPA Approvals for Tai&#039;ai (Telitacicept) in Sj\u00f6gren&#039;s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\/APRIL Inhibitor Franchise\" \/>\n<meta property=\"og:description\" content=\"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China&#039;s National Medical Products Administration (NMPA) has granted two additional indication approvals for Tai&#039;ai (telitacicept): the injection formulation for Sj\u00f6gren&#039;s syndrome (sicca syndrome) and the pre-filled syringe injection for IgA nephropathy, expanding the therapeutic reach of the world&#039;s first dual-targeting BLyS\/APRIL inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67791\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T15:10:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T15:10:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67791#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67791\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RemeGen Secures Dual NMPA Approvals for Tai&#8217;ai (Telitacicept) in Sj\u00f6gren&#8217;s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\\\/APRIL Inhibitor Franchise\",\"datePublished\":\"2026-06-09T15:10:43+00:00\",\"dateModified\":\"2026-06-09T15:10:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67791\"},\"wordCount\":411,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"HKG: 9995\",\"Product approvals\",\"RemeGen\",\"SHA: 688331\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67791#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67791\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67791\",\"name\":\"RemeGen Secures Dual NMPA Approvals for Tai'ai (Telitacicept) in Sj\u00f6gren's Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\\\/APRIL Inhibitor Franchise - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-09T15:10:43+00:00\",\"dateModified\":\"2026-06-09T15:10:45+00:00\",\"description\":\"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China's National Medical Products Administration (NMPA) has granted two additional indication approvals for Tai'ai (telitacicept): the injection formulation for Sj\u00f6gren's syndrome (sicca syndrome) and the pre-filled syringe injection for IgA nephropathy, expanding the therapeutic reach of the world's first dual-targeting BLyS\\\/APRIL inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67791#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67791\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67791#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RemeGen Secures Dual NMPA Approvals for Tai&#8217;ai (Telitacicept) in Sj\u00f6gren&#8217;s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\\\/APRIL Inhibitor Franchise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RemeGen Secures Dual NMPA Approvals for Tai'ai (Telitacicept) in Sj\u00f6gren's Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\/APRIL Inhibitor Franchise - Insight, China&#039;s Pharmaceutical Industry","description":"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China's National Medical Products Administration (NMPA) has granted two additional indication approvals for Tai'ai (telitacicept): the injection formulation for Sj\u00f6gren's syndrome (sicca syndrome) and the pre-filled syringe injection for IgA nephropathy, expanding the therapeutic reach of the world's first dual-targeting BLyS\/APRIL inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67791","og_locale":"en_US","og_type":"article","og_title":"RemeGen Secures Dual NMPA Approvals for Tai'ai (Telitacicept) in Sj\u00f6gren's Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\/APRIL Inhibitor Franchise","og_description":"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China's National Medical Products Administration (NMPA) has granted two additional indication approvals for Tai'ai (telitacicept): the injection formulation for Sj\u00f6gren's syndrome (sicca syndrome) and the pre-filled syringe injection for IgA nephropathy, expanding the therapeutic reach of the world's first dual-targeting BLyS\/APRIL inhibitor.","og_url":"https:\/\/flcube.com\/?p=67791","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-09T15:10:43+00:00","article_modified_time":"2026-06-09T15:10:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67791#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67791"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RemeGen Secures Dual NMPA Approvals for Tai&#8217;ai (Telitacicept) in Sj\u00f6gren&#8217;s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\/APRIL Inhibitor Franchise","datePublished":"2026-06-09T15:10:43+00:00","dateModified":"2026-06-09T15:10:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67791"},"wordCount":411,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","HKG: 9995","Product approvals","RemeGen","SHA: 688331"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67791#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67791","url":"https:\/\/flcube.com\/?p=67791","name":"RemeGen Secures Dual NMPA Approvals for Tai'ai (Telitacicept) in Sj\u00f6gren's Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\/APRIL Inhibitor Franchise - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-09T15:10:43+00:00","dateModified":"2026-06-09T15:10:45+00:00","description":"RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China's National Medical Products Administration (NMPA) has granted two additional indication approvals for Tai'ai (telitacicept): the injection formulation for Sj\u00f6gren's syndrome (sicca syndrome) and the pre-filled syringe injection for IgA nephropathy, expanding the therapeutic reach of the world's first dual-targeting BLyS\/APRIL inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67791#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67791"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67791#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RemeGen Secures Dual NMPA Approvals for Tai&#8217;ai (Telitacicept) in Sj\u00f6gren&#8217;s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS\/APRIL Inhibitor Franchise"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67791"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67791\/revisions"}],"predecessor-version":[{"id":67795,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67791\/revisions\/67795"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}